@article{17fa0b3ba85346e89c36076967fcd9ea,
title = "Right to Try, expanded access use, Project Facilitate, and clinical trial reform",
author = "Reddy, {N. K.} and V. Subbiah",
note = "Funding Information: VS is supported by a grant from the National Institutes of Health [grant number R01CA242845]; MD Anderson is supported by Cancer Center Support Grant [grant number P30 CA016672]. VS reports a grant and advisory board/consultant position with Eli Lilly/Loxo Oncology during the conduct of the study; research grants from Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, BergHealth, Incyte, Fujifilm, D3, Pfizer, MultiVir, Amgen, AbbVie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, UT MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, PharmaMar, and Medimmune; an advisory board/consultant position with Helsinn, Incyte, QED Pharma, Daiichi-Sankyo, Signant Health, Relay therapeutics, Novartis, and Medimmune; travel funds from PharmaMar, Incyte, ASCO, and ESMO; and other support from Medscape, all outside the submitted work. NKR has declared no conflicts of interest. Funding Information: VS is supported by a grant from the National Institutes of Health [grant number R01CA242845 ]; MD Anderson is supported by Cancer Center Support Grant [grant number P30 CA016672 ]. ",
year = "2021",
month = sep,
doi = "10.1016/j.annonc.2021.06.016",
language = "English (US)",
volume = "32",
pages = "1083--1086",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",
}